1. National Institute of Clinical Excellence. Neuropathic pain in adults: pharmacological management in non-specialist settings, https://www.nice.org.uk/guidance/cg173 (2013, accessed 2 August 2019). [PubMed]
2. Montastruc F, Loo SY, Renoux C.Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993-2017. JAMA2018; 320: 2149–2151. [PMC free article] [PubMed] [Google Scholar]
3. Goodman CW, Brett AS.A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med2019; 179: 695–701. [PubMed] [Google Scholar]
4. Mack A.Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm2003; 9: 559–568. [PMC free article] [PubMed] [Google Scholar]
5. González-Bueno J, Calvo-Cidoncha E, Desongles-Corrales T, et al. DI-024 off-label use of gabapentin and pregabalin in a tertiary hospital. Eur J Hosp Pharm2015; 22: A84–A85. [Google Scholar]
6. NHS Digital. Prescription cost analysis: England, 2018 [PAS], https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018 (2019, accessed 12 August 2019).
7. Thorpe A, Taylor C.Calcium channel α2-δ ligands: gabapentin and pregabalin. In: Taylor J, Triggle D. (eds) Comprehensive medicinal chemistry II, vol. 8Boston, MA: Elsevier, 2007, pp. 227–246. [Google Scholar]
8. Satzinger G.Antiepileptics from gamma-aminobutyric acid. Arzneimittelforschung1994; 44: 261–266. [PubMed] [Google Scholar]
9. Silverman RB.From basic science to blockbuster drug: the discovery of lyrica. Angew Chem Int Ed Engl2008; 47: 3500–3504. [PubMed] [Google Scholar]
10. Patel R, Dickenson AH.Mechanisms of the gabapentinoids and α2δ-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect2016; 4: e00205. [PMC free article] [PubMed] [Google Scholar]
11. Su TZ, Lunney E, Campbell G, et al. Transport of gabapentin, a γ-amino acid drug, by system l α-amino acid transporters: a comparative study in astrocytes, synaptosomes, and CHO Cells. J Neurochem1995; 64: 2125–2131. [PubMed] [Google Scholar]
12. Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmaco*kinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmaco*kinet2010; 49: 661–669. [PubMed] [Google Scholar]
13. Takahashi Y, Nishimura T, Higuchi K, et al. Transport of pregabalin via L-type amino acid transporter 1 (SLC7A5) in human brain capillary endothelial cell line. Pharm Res2018; 35: 246. [PMC free article] [PubMed] [Google Scholar]
14. Buvanendran A, Kroin JS, Kari M, et al. Can a single dose of 300 mg of pregabalin reach acute antihyperalgesic levels in the central nervous system. Reg Anesth Pain Med2010; 35: 535–538. [PubMed] [Google Scholar]
15. Buvanendran A, Kroin JS, Della Valle CJ, et al. Cerebrospinal fluid neurotransmitter changes during the perioperative period in patients undergoing total knee replacement: a randomized trial. Anesth Analg2012; 114: 434–441. [PubMed] [Google Scholar]
16. Jackson CD, Clanahan MJ, Joglekar K, et al. Hold the gaba: a case of gabapentin-induced hepatotoxicity. Cureus2018; 10: e2269. [PMC free article] [PubMed] [Google Scholar]
17. Kim ES, Deeks ED.Gabapentin enacarbil: a review in restless legs syndrome. Drugs2016; 76: 879–887. [PubMed] [Google Scholar]
18. Swearingen D, Aronoff GM, Ciric S, et al. Pharmaco*kinetics of immediate release, extended release, and gastric retentive gabapentin formulations in healthy adults. Int J Clin Pharmacol Ther2018; 56: 231–238. [PMC free article] [PubMed] [Google Scholar]
19. Gee NS, Brown JP, Dissanayake VUK, et al. The novel anticonvulsant drug, gabapentin (neurontin), binds to the subunit of a calcium channel. J Biol Chem1996; 271: 5768–5776. [PubMed] [Google Scholar]
20. Doan L.Voltage-gated calcium channels and pain. Tech Reg Anesth Pain Manag2010; 14: 42–47. [Google Scholar]
21. Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion α2δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci2001; 21: 1868–1875. [PMC free article] [PubMed] [Google Scholar]
22. Nguyen D, Deng P, Matthews EA, et al. Enhanced pre-synaptic glutamate release in deep-dorsal horn contributes to calcium channel α2δ-1 protein mediated spinal sensitization and behavioral hypersensitivity. Mol Pain2009; 5: 6. [PMC free article] [PubMed] [Google Scholar]
23. Uchitel OD, Di Guilmi MN, Urbano FJ, et al. Acute modulation of calcium currents and synaptic transmission by gabapentinoids. Channels (Austin)2010; 4: 490–496. [PubMed] [Google Scholar]
24. Chincholkar M.Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. Br J Anaesth2018; 120: 1315–1334. [PubMed] [Google Scholar]
25. Bauer CS, Rahman W, Tran-Van-Minh A, et al. The anti-allodynic α2δ ligand pregabalin inhibits the trafficking of the calcium channel α2δ-1 subunit to presynaptic terminals in vivo. Biochem Soc Trans2010; 38: 525–528. [PubMed] [Google Scholar]
26. Zhou C, Luo ZD.Electrophysiological characterization of spinal neuron sensitization by elevated calcium channel alpha-2-delta-1 subunit protein. Eur J Pain2014; 18: 649–658. [PMC free article] [PubMed] [Google Scholar]
27. Suto T, Severino AL, Eisenach JC, et al. Gabapentin increases extracellular glutamatergic level in the locus coeruleus via astroglial glutamate transporter-dependent mechanisms. Neuropharmacology2014; 81: 95–100. [PMC free article] [PubMed] [Google Scholar]
28. Kimura M, Eisenach JC, Hayashida K.Gabapentin loses efficacy over time after nerve injury in rats: role of glutamate transporter-1 in the locus coeruleus. Pain2016; 157: 2024–2032. [PMC free article] [PubMed] [Google Scholar]
29. Lin HC, Huang YH, Chao TH, et al. Gabapentin reverses central hypersensitivity and suppresses medial prefrontal cortical glucose metabolism in rats with neuropathic pain. Mol Pain2014; 10: 63. [PMC free article] [PubMed] [Google Scholar]
30. Park J, Yu YP, Zhou C-Y, et al. Central mechanisms mediating thrombospondin-4-induced pain states. J Biol Chem2016; 291: 13335–13348. [PMC free article] [PubMed] [Google Scholar]
31. Ryu JH, Lee PB, Kim JH, et al. Effects of pregabalin on the activity of glutamate transporter type 3. Br J Anaesth2012; 109: 234–239. [PubMed] [Google Scholar]
32. Eroglu C, Allen NJ, Susman MW, et al. The gabapentin receptor α2δ-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell2009; 139: 380–392. [PMC free article] [PubMed] [Google Scholar]
33. Bannister K, Qu C, Navratilova E, et al. Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain2017; 158: 2386–2395. [PMC free article] [PubMed] [Google Scholar]
34. If*cku M, Iseki M, Hidaka I, et al. Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. Pain Med2011; 12: 1112–1116. [PubMed] [Google Scholar]
35. Toth C.Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med2010; 11: 456–465. [PubMed] [Google Scholar]
36. Bockbrader HN, Budhwani MN, Wesche DL.Gabapentin to pregabalin therapy transition: a pharmaco*kinetic simulation. Am J Ther2013; 20: 32–36. [PubMed] [Google Scholar]
37. Toth C.Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf2014; 5: 38–56. [PMC free article] [PubMed] [Google Scholar]
38. National Institute for Health and Care Excellence. British National Formulary, Pregabalin, https://bnf.nice.org.uk/drug/pregabalin.html#indicationsAndDoses (accessed 6 December 2019).
39. National Institute for Health and Care Excellence. British National Formulary, Gabapentin, https://bnf.nice.org.uk/drug/gabapentin.html#indicationsAndDoses (accessed 6 December 2019).
40. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev2017; 6: CD007938. [PMC free article] [PubMed] [Google Scholar]
41. Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev2019; 1: CD007076. [PMC free article] [PubMed] [Google Scholar]
42. Zaccara G, Gangemi P, Perucca P, et al. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia2011; 52: 826–836. [PubMed] [Google Scholar]
43. Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med2017; 14: e1002396. [PMC free article] [PubMed] [Google Scholar]
44. Medicines and Healthcare Products Regulatory Agency. Gabapentin (Neurontin): risk of severe respiratory depression, https://www.gov.uk/drug-safety-update/gabapentin-neurontin-risk-of-severe-respiratory-depression (2017, accessed 29 September 2019).
45. Ryvlin P, Perucca E, Rheims S.Pregabalin for the management of partial epilepsy. Neuropsychiatr Dis Treat2008; 4: 1211–1224. [PMC free article] [PubMed] [Google Scholar]
46. Hoppe C, Rademacher M, Hoffmann JM, et al. Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients. Seizure2008; 17: 327–332. [PubMed] [Google Scholar]
47. Cabrera J, Emir B, Dills D, et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin2012; 28: 1027–1037. [PubMed] [Google Scholar]
48. Calkins A, Shurman J, Jaros M, et al. Peripheral edema and weight gain in adult patients with painful Diabetic Peripheral Neuropathy (DPN) receiving gabapentin enacarbil (GEn) or pregabalin enrolled in a randomized phase 2 trial (I6–1.004). Neurology2014; 82: I6–1004. [Google Scholar]
49. Murphy N, Mockler M, Ryder M, et al. Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain. J Card Fail2007; 13: 227–229. [PubMed] [Google Scholar]
50. Ho Macdonald EM, Luo J, Gomes T, et al. Pregabalin and heart failure: a population-based study. Pharmacoepidemiol Drug Saf2017; 26: 1087–1092. [PubMed] [Google Scholar]
51. Evoy KE, Morrison MD, Saklad SR.Abuse and misuse of pregabalin and gabapentin. Drugs2017; 77: 403–426. [PubMed] [Google Scholar]
52. Smith BH, Higgins C, Baldacchino A, et al. Substance misuse of gabapentin. Br J Gen Pract2012; 62: 406–407. [PMC free article] [PubMed] [Google Scholar]
53. Bonnet U, Scherbaum N.How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol2017; 27: 1185–1215. [PubMed] [Google Scholar]
54. Specialist Pharmacy Services. Gabapentin and pregabalin offender health audit report and audit tool, https://www.sps.nhs.uk/articles/gabapentin-and-pregabalin-offender-health-audit-report-and-audit-tool/ (2013, accessed 30 September 2019).
55. GOV.UK. Pregabalin and gabapentin to be controlled as class C drugs, https://www.gov.uk/government/news/pregabalin-and-gabapentin-to-be-controlled-as-class-c-drugs (accessed 29 September 2019).
56. Mersfelder TL, Nichols WH.Gabapentin: abuse, dependence and withdrawal. Ann Pharmacother2016; 50: 229–233. [PubMed] [Google Scholar]
57. Barrett J, Kittler L, Singarajah C.Acute pregabalin withdrawal: a case report and review of the literature. Southwest J Pulm Crit Care2015; 10: 306–310. [Google Scholar]
58. Mah L, Hart M.Gabapentin withdrawal: case report in an older adult and review of the literature. J Am Geriatr Soc2013; 61: 1635–1637. [PubMed] [Google Scholar]
59. Zand L, McKian KP, Qian Q.Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. Am J Med2010; 123: 367–373. [PubMed] [Google Scholar]
60. Raouf M, Atkinson TJ, Crumb MW, et al. Rational dosing of gabapentin and pregabalin in chronic kidney disease. J Pain Res2017; 10: 275–278. [PMC free article] [PubMed] [Google Scholar]
61. Attal N, Bouhassira D.Pharmacotherapy of neuropathic pain. Pain2015; 156: S104–S114. [PubMed] [Google Scholar]
62. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol2015; 14: 162–173. [PMC free article] [PubMed] [Google Scholar]
63. Patel R, Bauer CS, Nieto-Rostro M, et al. α2δ-1 gene deletion affects somatosensory neuron function and delays mechanical hypersensitivity in response to peripheral nerve damage. J Neurosci2013; 33: 16412–16426. [PMC free article] [PubMed] [Google Scholar]
64. Rhee TG, Ross JS.Association between industry payments to physicians and gabapentinoid prescribing. JAMA Intern Med. Epub ahead of print 8 July 2019. DOI: 10.1001/jamainternmed.2019.1082. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
65. National Institute for Health and Care Excellence. Low back pain and sciatica in over 16s: assessment and management, https://www.nice.org.uk/guidance/NG59/chapter/Recommendations#non-invasive-treatments-for-low-back-pain-and-sciatica (accessed 12 August 2019). [PubMed]
66. Shanthanna H, Gilron I, Rajarathinam M, et al. Benefits and safety of gabapentinoids in chronic low back pain: a systematic review and meta-analysis of randomized controlled trials. PLoS Med2017; 14: e1002369. [PMC free article] [PubMed] [Google Scholar]
67. Derry S, Cording M, Wiffen PJ, et al. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev2016; 9: CD011790. [PMC free article] [PubMed] [Google Scholar]
68. Cooper TE, Derry S, Wiffen PJ, et al. Gabapentin for fibromyalgia pain in adults. Cochrane Database Syst Rev2017; 1: CD012188. [PMC free article] [PubMed] [Google Scholar]
69. Schmidt PC, Ruchelli G, Mackey SC, et al. Perioperative gabapentinoids choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology2013; 119: 1215–1221. [PubMed] [Google Scholar]
70. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain2016; 17: 131–157. [PubMed] [Google Scholar]
71. Fabritius ML, Strom C, Koyuncu S, et al. Benefit and harm of pregabalin in acute pain treatment: a systematic review with meta-analyses and trial sequential analyses. Br J Anaesth2017; 119: 775–791. [PubMed] [Google Scholar]
72. Zhang J, Ho KY, Wang Y.Efficacy of pregabalin in acute postoperative pain: a meta-analysis. Br J Anaesth2011; 106: 454–462. [PubMed] [Google Scholar]
73. Hurley RW, Cohen SP, Williams KA, et al. The analgesic effects of perioperative gabapentin on postoperative pain: a meta-analysis. Reg Anesth Pain Med2006; 31: 237–247. [PubMed] [Google Scholar]
74. Peng PW, Wijeysundera DN, Li CC.Use of gabapentin for perioperative pain control – a meta-analysis. Pain Res Manag2007; 12: 85–92. [PMC free article] [PubMed] [Google Scholar]
75. Mishriky BM, Waldron NH, Habib AS.Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. Br J Anaesth2014; 114: 10–31. [PubMed] [Google Scholar]
76. Doleman B, Heinink TP, Read DJ, et al. A systematic review and meta-regression analysis of prophylactic gabapentin for postoperative pain. Anaesthesia2015; 70: 1186–1204. [PubMed] [Google Scholar]
77. Hah J, Mackey SC, Schmidt P, et al. Effect of perioperative gabapentin on postoperative pain resolution and opioid cessation in a mixed surgical cohort. JAMA Surg2018; 153: 303–311. [PMC free article] [PubMed] [Google Scholar]
78. Myhre M, Diep LM, Stubhaug A.Pregabalin has analgesic, ventilatory, and cognitive effects in combination with remifentanil. Anesthesiology2016; 124: 141–149. [PubMed] [Google Scholar]
79. Deljou A, Hedrick SJ, Portner ER, et al. Pattern of perioperative gabapentinoid use and risk for postoperative naloxone administration. Br J Anaesth2018; 120: 798–806. [PubMed] [Google Scholar]
80. Reddi D.Preventing chronic postoperative pain. Anaesthesia2016; 71: 64–71. [PubMed] [Google Scholar]
81. Chaparro LE, Smith SA, Moore RA, et al. Pharmacotherapy for the prevention of chronic pain after surgery in adults. Cochrane Database Syst Rev2013; 7: CD008307. [PMC free article] [PubMed] [Google Scholar]
82. NHS Scotland Effective Prescribing and Therapeutics Branch. Chronic pain prescribing strategy: gabapentinoid prescribing, https://www.therapeutics.scot.nhs.uk/pain/ (accessed 6 December 2019).
83. Perucca E, Berlowitz D, Birnbaum A, et al. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res2006; 68: S49–S63. [PubMed] [Google Scholar]
84. Eipe N, Penning J, Yazdi F, et al. Perioperative use of pregabalin for acute pain – a systematic review and meta-analysis. Pain2015; 156: 1284–1300. [PubMed] [Google Scholar]
85. Simpson G, Jackson M.Perioperative management of opioid-tolerant patients. BJA Educ2017; 17: 124–128. [Google Scholar]
